Autologous hematopoietic stem cell transplant for the treatment of refractory myasthenia gravis with anti‐muscle specific kinase antibodies
Authors:
- 26 December 2022
- journal article
- research article
- Published by Wiley in Muscle & Nerve
- Vol. 67 (2) , 154-157
Abstract
Introduction/Aims: Up to 25% of patients with myasthenia gravis (MG) have refractory disease despite trials of multiple immunosuppressants. Several case series describe acetylcholine receptor antibody‐positive (AChR) MG patients treated with autologous hematopoietic stem cell transplant (HSCT). In this report, we describe three patients with anti‐muscle‐specific kinase (MuSK) MG treated with HSCT.Methods: We included all patients who had undergone HSCT with anti‐MuSK myasthenia gravis identified through the records of the Alberta Blood and Marrow Transplant Program. We collected demographic and clinical data including validated MG scales as well as questionnaire data.Results: All 3 patients had severe disease (Myasthenia Gravis Foundation of America score IVb‐V) and were refractory to multiple treatments, including rituximab. All patients improved with no clinical manifestations or mild symptoms and remained as such for 2, 3.5, and 5.5 y. Adverse events ranged from treatable infections and transient dyspnea to persistent fatigue and premature menopause. The average worst Myasthenia Gravis Activities of Daily Living (MG‐ADL) scores improved from 14.7 before to 0.3 after HSCT. The mean worst Myasthenia Gravis Quality of Life Questionnaire (MG‐QoL15) scores improved from 26.7 to 0. All patients reported they would undergo transplant again for their MG.Discussion: We describe three patients with anti‐MuSK MG treated with HSCT, all of whom became symptom free from MG with a tolerable side effect profile. In patients with severe refractory anti‐MuSK MG, it may be reasonable to consider HSCT.Keywords
This publication has 14 references indexed in Scilit:
- Successful autologous haematopoietic stem cell transplantation for refractory myasthenia gravis – a case reportNeuromuscular Disorders, 2017
- Myasthenia Gravis Treated With Autologous Hematopoietic Stem Cell TransplantationJAMA Neurology, 2016
- International clinimetric evaluation of the MG‐QOL15, resulting in slight revision and subsequent validation of the MG‐QOL15rMuscle & Nerve, 2016
- Association of Nonmyeloablative Hematopoietic Stem Cell Transplantation With Neurological Disability in Patients With Relapsing-Remitting Multiple SclerosisJAMA, 2015
- Transplantation for Autoimmune Diseases in North and South America: A Report of the Center for International Blood and Marrow Transplant ResearchTransplantation and Cellular Therapy, 2012
- Hematopoietic Cell Transplantation for Autoimmune Disease: Updates from Europe and the United StatesTransplantation and Cellular Therapy, 2010
- Allogeneic Hematopoietic Cell Transplantation for Refractory Myasthenia GravisArchives of Neurology, 2009
- Development of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases: role of conditioning regimen usedBlood, 2006
- Myasthenia gravis: recommendations for clinical research standardsThe Annals of Thoracic Surgery, 2000
- Myasthenia gravis activities of daily living profileNeurology, 1999